Single Chelator–Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer

© 2024 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: https://jnm.snmjournals.org/page/permissions.

Author Information

Khanh-Van Ho¹,²,
David S. Tatum³,
Lisa Watkinson²,⁴,
Terry Carmack²,⁴,
Fang Jia⁵,
Alessandro Mascioni⁵,
Charles A. Maitz⁶,⁷,
Darren Magda³ and
Carolyn J. Anderson¹,²,⁸,⁹

¹Department of Chemistry, University of Missouri, Columbia, Missouri;
²Molecular Imaging and Theranostics Center, University of Missouri, Columbia, Missouri;
³Lumiphore Inc., Berkeley, California;
⁴Research Service, Harry S. Truman Memorial Veterans’ Hospital, Columbia, Missouri;
⁵ImaginAb Inc., Inglewood, California;
⁶Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri;
⁷MU Research Reactor, University of Missouri, Columbia, Missouri;
⁸Department of Radiology, University of Missouri, Columbia, Missouri; and
⁹Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri